Welcome to our dedicated page for U S PHYSICAL THERAPY /NV SEC filings (Ticker: USPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on U S PHYSICAL THERAPY /NV's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into U S PHYSICAL THERAPY /NV's regulatory disclosures and financial reporting.
U.S. Physical Therapy, Inc. (NYSE: USPH) reported a Regulation FD disclosure in a Form 8-K stating that on August 12, 2025 the company updated its investor presentation. The presentation provides an overview of the company and is posted on the company website under Investor Relations.
The filing identifies Exhibit 99.1 as the "USPH Investor's Presentation for the Three and Six months Ended June 30, 2025." The company expressly states the information is furnished, not filed, and therefore is not subject to Section 18 liabilities or automatically incorporated by reference into registration statements.
US Physical Therapy (USPH) reported a proposed sale of 1,792 shares of Class A common stock on the NYSE through J.P. Morgan Securities, with an aggregate market value of $155,124.48. The filing states the shares were acquired on 05/20/2025 by vesting of restricted stock grants (grants issued from 08/16/2021 to 02/24/2025) and lists an approximate sale date of 08/11/2025 with payment in cash.
Against total outstanding shares of 15,190,000, the 1,792-share notice represents about 0.0118% of the company’s shares outstanding. The filer reported no securities sold in the past three months. The form includes the required compliance representation under Rule 144 and identifies J.P. Morgan Securities LLC as the broker.
U.S. Physical Therapy, Inc. (NYSE: USPH) hosted a conference call and webcast on August 7, 2025 to discuss results for the three and six months ended June 30, 2025. The company furnished the conference call transcript as Exhibit 99.1 to this Current Report and stated the materials are furnished, not filed, so they are not subject to Section 18 liabilities and are not incorporated by reference unless expressly provided.
This 8-K itself does not present financial statements or earnings figures; it makes management commentary and the call transcript available to investors as a supplemental disclosure.
Q2 2025 performance (USPH)
- Net revenue rose 18% YoY to $197.3 m; six-month revenue $381.1 m (+18%).
- Net income attributable to shareholders jumped 65% to $12.4 m; diluted EPS $0.58 versus $0.47.
- Operating income improved 60% to $24.9 m; margin expanded to 12.6% (9.3% LY) aided by a $0.8 m gain on contingent earn-out revaluation.
- Gross margin inched up to 21.1% from 20.3% despite higher salary and rent expense.
- Cash from operations YTD $30.2 m (-10%); cash balance fell to $34.1 m after $6.9 m of acquisitions and $13.7 m in dividends.
- Debt profile: revolver borrowings increased to $24.5 m (11.0 m YE); term loan reduced to $127.1 m. Interest expense up 22% YoY.
- Clinic count reached 768 (+46 YoY) after 6 openings, 4 closures and two bolt-on deals (3 clinics + home-care business).
- Equity climbed to $500.8 m; quarterly dividend lifted to $0.45.
Other notes: No impairment triggers were identified. New U.S. tax legislation signed 4 Jul 25 is not yet reflected. Management continues acquisitive growth strategy.